November 15, 2026 · Regulatory Affairs
DEA's November 29 Schedule III Supply-Chain Deadline: What Canadian Cannabis Companies Should Know
By Mussarat Fatima

The United States Drug Enforcement Administration has moved from debating medical cannabis rescheduling to enforcing it. On 30 October 2026, the DEA issued the first federal registrations to state-licensed medical cannabis dispensaries under Schedule III, and it set a hard date of 29 November 2026 for those registrants to verify their trading partners and build what the agency calls compliant supply chains. For Canadian licensed producers watching the US market, this is the clearest sign yet that a federal medical cannabis pathway is now operating, even though it remains narrow.
This article explains what the 29 November deadline requires, how the April 2026 Schedule III order created this pathway, what the change does and does not do, and why Canadian producers and exporters should pay attention even though the registration itself is a United States matter.
What is the 29 November deadline?
The 29 November 2026 deadline is the date by which newly registered medical cannabis businesses, and businesses whose applications are still pending, must confirm that every supplier and customer in their chain is either a DEA registrant or a timely applicant. In short, a Schedule III medical cannabis operator must trade only with other participants in the federal system. The DEA released the supporting guidance alongside the first registrations on 30 October 2026.
A timely applicant is a business that applied for registration during the initial application window. Timely applicants may keep transacting with each other and with newly registered companies while their own applications are pending. A business that did not apply in that window is not blocked from registering later, but it loses timely applicant status, which affects who it can lawfully trade with in the meantime.
How we got here: the April 2026 Schedule III order
The pathway traces back to an order signed in late April 2026 and published in the Federal Register on 28 April 2026. Acting under the Controlled Substances Act, the order moved two categories of marijuana from Schedule I to Schedule III: marijuana contained in an FDA-approved drug product, and marijuana manufactured, distributed or dispensed under a qualifying state-issued medical cannabis licence.
The order did not reschedule marijuana as a whole. Everything outside those two categories, including adult-use product, cannabis held without a qualifying medical licence, and synthetically derived THC, stays in Schedule I. That distinction is the single most important thing to understand about this change. It is a targeted, medical-only pathway, not nationwide legalization.
The first federal registrations
On 30 October 2026, the DEA issued the first federal registrations to more than 900 state-licensed medical cannabis dispensaries across seven medical-only states. These are standard DEA registrations under existing processes, not a new licence category. A state licence alone does not confer federal registration. Applicants must clear a pre-registration investigation, which has included on-site review, and registrants must then comply with the federal security, recordkeeping, inventory-control, labelling and disposal requirements that apply to Schedule III substances.
No registrations have yet been issued to operators in adult-use states, because adult-use cannabis is not covered by the order. The practical effect is a growing, federally recognized medical cannabis supply chain that sits apart from the much larger adult-use market.
What registrants must do by 29 November
The core obligation is diligence on every trading partner. For each supplier and customer, a registrant should:
- Obtain proof that the counterparty is a DEA registrant or a timely applicant, such as a certificate of registration or a submission confirmation.
- Confirm the counterparty holds an active state licence for the activity.
- Keep records of that verification, so the diligence can be shown later.
According to the DEA guidance, product acquired before the guidance took effect, including inventory from businesses that are not in the federal system, may still be sold through. There is also a narrow allowance for sending small, state-mandated testing samples to a non-registered in-state laboratory where using a registered lab would conflict with state law, provided detailed records are kept. Operators who miss the deadline or keep dealing outside the federal system risk denial of pending applications or revocation of their registrations.
What the change does not do
It is as important to be clear about the limits. Adult-use cannabis remains in Schedule I and sits outside both the registration pathway and the associated tax relief. The broader question of whether marijuana as a whole should move to Schedule III was the subject of a separate administrative hearing held in mid-2026, followed by written briefing later in the year. No decision has been issued on that broader rescheduling, and the DEA has given no timeline. Companies should not read the medical-only registrations as a signal that full rescheduling is imminent.
The 280E tax angle
Because the covered medical activities now involve a Schedule III substance rather than a Schedule I substance, the order is understood to lift the Internal Revenue Code Section 280E deduction disallowance for those activities. Section 280E has long prevented cannabis businesses from deducting ordinary operating expenses. The United States Treasury and the Internal Revenue Service announced that transition and allocation guidance would follow, and that guidance was still pending at the time of writing. Businesses with both medical and adult-use operations should expect to segregate their medical-licensed entities, inventory, revenue and expenses, and should confirm the tax treatment with a qualified United States tax advisor rather than assuming relief applies automatically.
Why this matters for Canadian licensed producers
Canadian producers cannot hold these DEA registrations, and this order does not open the US border to Canadian cannabis. So why follow it closely? Because it reshapes the counterparties, the quality expectations and the tax position of the partners a Canadian company would work with if and when cross-border medical trade becomes possible. As we explained in our analysis of what DEA Schedule III means for Canadian LPs, a federally recognized medical market rewards operators who can prove a disciplined quality system, not just a state licence.
The lesson Canadian producers already learned in Europe applies here. In Germany, the ability to prove EU-GMP quality is what separates exporters who win shelf space from those who do not. A United States medical pathway built on federal registration, security and recordkeeping will favour the same strengths. Canadian producers that keep a mature quality system, a capable Quality Assurance Person function, and clean documentation are the ones that will be ready to partner when a lawful route appears.
There is also a direct compliance parallel at home. Canadian companies that handle controlled substances already live with federal scheduling, security clearances and dealer licensing under the Controlled Substances Regulations. The discipline a DEA registrant must show, verified trading partners, tight records and security controls, is familiar territory for any Canadian operator that has built a controlled-substance compliance program.
Supply-chain verification checklist
Operators subject to the deadline, and the Canadian partners who advise them, can use this checklist as a starting point.
- List every active supplier and customer of Schedule III medical cannabis.
- Collect each counterparty's DEA registration certificate or submission confirmation.
- Confirm each counterparty holds an active state licence for its role.
- Document the verification and the date it was completed.
- Identify pre-guidance inventory that may still be sold, and record its source.
- Set a re-verification schedule, because a counterparty's status can change.
- Confirm federal security, recordkeeping, inventory and disposal controls are in place.
Common mistakes to avoid
- Assuming all marijuana is now Schedule III. Only FDA-approved cannabis drug products and state-licensed medical cannabis are covered. Adult-use stays Schedule I.
- Treating a state licence as federal registration. They are separate. Federal registration requires its own application and investigation.
- Skipping the paper trail. Verifying a partner verbally is not enough. Keep the certificate or confirmation on file.
- Assuming automatic 280E relief. Treasury and IRS guidance is still pending. Confirm the tax treatment with a qualified US advisor.
- Expecting an open Canada to US cannabis trade. This order does not authorize importing Canadian cannabis into the United States.
How MFLRC can help
MF License and Regulatory Consultants helps Canadian licensed producers build the quality systems, documentation and controlled-substance compliance that an international medical market rewards. We develop GMP and GPP quality systems, prepare sites for EU-GMP and GACP certification, draft SOPs and quality agreements, run audits and mock inspections, and advise on licensing and change-of-control obligations. With more than twenty years of quality and regulatory experience across pharmaceuticals, cannabis and controlled substances, our team helps you be the partner a federally regulated buyer can trust.
Planning for the United States or other export markets? Book an MFLRC consultation and make sure your quality system and compliance records are export-ready before the opportunity arrives.
Frequently asked questions
What is the 29 November 2026 DEA deadline?
It is the date by which Schedule III medical cannabis registrants and timely applicants must verify that they buy from and sell to only DEA registrants or timely applicants, and keep records of that verification. The DEA released the guidance on 30 October 2026.
Did the DEA reschedule all marijuana to Schedule III?
No. The April 2026 order moved only FDA-approved cannabis drug products and state-licensed medical cannabis to Schedule III. Adult-use cannabis and other categories remain in Schedule I, and the broader rescheduling question is still undecided.
What is a timely applicant?
A timely applicant is a business that applied for registration during the initial application window. Timely applicants may keep transacting with each other and with newly registered businesses while their applications are pending. Businesses that did not apply in that window can still register later but lose timely applicant status.
Can Canadian producers register with the DEA or export to these dispensaries?
No. The registration pathway is for United States operators, and the order does not authorize importing Canadian cannabis into the United States. The relevance for Canadian producers is strategic: it signals the quality and compliance standards a future partner would expect.
Does Schedule III fix the 280E tax problem?
The order is understood to lift the Section 280E deduction disallowance for covered medical activities, but Treasury and IRS transition guidance was still pending at the time of writing. Operators should confirm the treatment with a qualified United States tax advisor.
What happens if a registrant misses the deadline?
According to the DEA guidance, operators who miss the deadline or keep dealing with businesses outside the federal system risk denial of their pending applications or revocation of their registrations.
Conclusion
The 29 November deadline marks the point where federal medical cannabis in the United States stops being theoretical and starts imposing real supply-chain discipline. The pathway is narrow, medical only, and built on the same pillars Canadian producers already respect: registration, verified partners, security and records. For Canadian companies, the message is not to wait for the border to open, but to keep a quality system and compliance file strong enough to be chosen the moment a lawful route does.
Sources and references
Downloadable Resource
DEA November 29 Supply-Chain Readiness Checklist
A one-page, branded checklist to help cannabis operators and their Canadian partners verify trading partners, keep diligence records and stay inside the Schedule III supply chain.
File: MFLRC-DEA-Supply-Chain-Checklist.pdf
Share with others
Tags
